Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2003
10/30/2003WO2003089667A1 Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
10/30/2003WO2003089642A1 Oligonucleotide compositions and their use for the modulation of immune responses
10/30/2003WO2003089638A1 Nucleic acid molecule encoding a variant ddah 1 protein and uses thereof
10/30/2003WO2003089615A2 Antiviral inhibitions of capsid proteins
10/30/2003WO2003089593A2 Adjuvant enhanced immunotherapy
10/30/2003WO2003089583A2 Tissue specific genes and gene clusters
10/30/2003WO2003089573A2 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
10/30/2003WO2003089568A2 Method of inhibiting restenosis
10/30/2003WO2003089427A1 Indol-2-ones as selective inhibitors of cyclooxygenase-2
10/30/2003WO2003089418A1 Indane acetic acid derivatives and their use as pharmaceutical agents
10/30/2003WO2003089405A1 Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition
10/30/2003WO2003089007A1 Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu
10/30/2003WO2003089006A1 Combination of an agent that attenuates topoisomerase 1 activity and an agent that inhibits heat shock protein 90 for use in chemotherapy
10/30/2003WO2003089003A1 Methods of treatment and diagnosis of patients with hepatitis c infection
10/30/2003WO2003089002A1 Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia
10/30/2003WO2003089001A1 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
10/30/2003WO2003089000A2 Anti-hiv composition, production method thereof and medicament
10/30/2003WO2003088986A1 Curcumin for the prevention and/or treatment of tissue damage
10/30/2003WO2003088985A2 Use of compositions containing petasites for treating diseases
10/30/2003WO2003088984A1 Compositions and methods for augmenting kidney function
10/30/2003WO2003088983A1 Use of topical compositions for the control of microbial diseases of the nail
10/30/2003WO2003088978A1 Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
10/30/2003WO2003088976A1 Method for treating and preventing hyperparathyroidism
10/30/2003WO2003088973A1 Combination of brimonidine and timolol for topical ophthalmic use
10/30/2003WO2003088967A1 (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists
10/30/2003WO2003088962A1 Combination therapy using a ppar alpha/gamma agonist
10/30/2003WO2003088961A1 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
10/30/2003WO2003088958A2 Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease
10/30/2003WO2003088954A1 Combination therapy for the treatment of cancer
10/30/2003WO2003088943A1 Dry powder compositions
10/30/2003WO2003088920A2 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics
10/30/2003WO2003088918A2 PHARMACEUTICAL COMPOSITIONS CONTAINING α3β4 NICOTINIC RECEPTOR ANTAGONISTS AND METHODS OF THEIR USE
10/30/2003WO2003088915A2 Novel sodium channel blockers
10/30/2003WO2003088909A2 Methods for modulating phototoxicity
10/30/2003WO2003088904A2 Screening and therapeutic methods for treating circadian rhythm disorders
10/30/2003WO2003088903A2 Compounds, compositions, and methods
10/30/2003WO2003088900A2 Solid forms of salts with tyrosine kinase activity
10/30/2003WO2003088898A2 Compositions and methods for the diagnosis and treatment of tumor
10/30/2003WO2003088749A1 Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease
10/30/2003WO2003073841A3 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
10/30/2003WO2003066579A3 Novel bicyclic hydroxamates as inhibitors of histone deacetylase
10/30/2003WO2003063796A3 Heterocyclic arylsulfonamidobenzylic compounds
10/30/2003WO2003057919A3 The use of histamine h4 receptor antagonist for the treatment of inflammatory response
10/30/2003WO2003053353A3 Administration of vasopeptidase inhibitors to reduce pulse pressure
10/30/2003WO2003051833A3 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
10/30/2003WO2003051831A3 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
10/30/2003WO2003051378A3 Pharmaceutical composition for topical treatment of skin disorders and skin wounds
10/30/2003WO2003051293A3 Antidiabetic formulation and method
10/30/2003WO2003049680A3 Compositions containing both sedative and non-sedative antihistamines
10/30/2003WO2003047697A3 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
10/30/2003WO2003045319A3 Targeted therapeutics and uses thereof
10/30/2003WO2003043569A3 Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
10/30/2003WO2003034903A3 Psma antibodies and protein multimers
10/30/2003WO2003031568A3 Intracellular signaling molecules
10/30/2003WO2003029428A3 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease
10/30/2003WO2003029264A3 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
10/30/2003WO2003028477A3 Method of hydration ; infusion packet system(s), support member(s), delivery system(s), and method(s) ; with business model(s) and method(s)
10/30/2003WO2003027143A3 Gene and protein relating to hepatocellular carcinoma
10/30/2003WO2003025199A3 Mid 4460, a human tyrosine phosphatase family member and uses therefor
10/30/2003WO2003024436A3 Method for treating skin disorders
10/30/2003WO2003020287A3 Methods for the treatment of chronic pain anc compositions therefor
10/30/2003WO2003016549A3 Nucleic-acid associated proteins
10/30/2003WO2003015608A3 Combination therapy for the treatment of cancer
10/30/2003WO2003012051A3 Inhibitor of dna methylation
10/30/2003WO2003008635A8 η-SECRETASE IN VITRO SCREENING ASSAY
10/30/2003WO2003000717A3 Identification of ses-3 (spr-5) in c. elegans and the uses of the same
10/30/2003WO2002102229A3 Diagnosing tumorigenicity and determining resistance to anticancer therapy
10/30/2003WO2002099041A3 Ces2s as modifiers of the p53 pathway and methods of use
10/30/2003WO2002098391A3 Process for preparing granular compositions
10/30/2003WO2002094876A3 Methods and compositions for treating respiratory mucin production associated disease conditions
10/30/2003WO2002087563A3 Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
10/30/2003WO2002085458A3 Use of nk-1 receptor antagonists against benign prostatic hyperplasia
10/30/2003WO2002084294A3 Gastrointestinal glutathione peroxidase in hepatitis c virus infections
10/30/2003WO2002072106A3 Combined method for treating hormono-dependent disorders with exemestane
10/30/2003WO2002070741A3 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
10/30/2003WO2002069901A3 Cathepsin cysteine protease inhibitors
10/30/2003WO2002068617A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
10/30/2003WO2002064784A3 Yeast strain of saccharomyces cerevisiae with functional expression of a glut transporter
10/30/2003WO2002060474A3 Mixtures of mushroom enzymes and the use thereof for treating maldigestion
10/30/2003WO2002059327A3 Sulfatases and methods of use thereof
10/30/2003WO2002059283A3 Nucleic acid modification enzymes
10/30/2003WO2002034783A3 Transmembrane proteins
10/30/2003WO2002018583A9 Modified polypeptides stabilized in a desired conformation and methods for producing same
10/30/2003WO2002002638A3 Methods for treating rheumatic diseases using a soluble ctla4 molecule
10/30/2003WO2001085995A3 Identification of neural defects associated with the nucleosom al assembly protein 1l2 gene
10/30/2003WO2001085154A8 Method of treating immune pathologies with low dose estrogen
10/30/2003US20030204863 Nav2 channel gene-deficient non-human animals
10/30/2003US20030203976 Anti-angiogenic compositions and methods of use
10/30/2003US20030203973 Administering triethylenetetramine to lower copper value of myocardium; for treatment of diabetes
10/30/2003US20030203969 Pharmaceutically active aromatic guanylhydrazones
10/30/2003US20030203961 A taxane joined by a hydrolyzable bond to one or more oligomers that containing a polyethylene glycol group and a tert-amide group
10/30/2003US20030203956 Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
10/30/2003US20030203947 Activator of PPAR delta
10/30/2003US20030203946 Glucagon antagonists/inverse agonists
10/30/2003US20030203945 Coupling a heterocyclic compound containing amine group with a 4-nitrophenyl-1-oxycarbonyl or derivative useful for the treatment of neurological conditions
10/30/2003US20030203929 Microtubule stabilizing compounds
10/30/2003US20030203926 For treatment of inflammatory or autoimmune condition, viral infection, cancer
10/30/2003US20030203924 Combination for treating susceptible tumor comprising (S)-2-(5-(((1,2-dihydro-3-methyl-1-oxobenzo(f) quinazolin-9-yl)methyl)amino)-1-oxo-2-isoindolinyl)glutaric acid and folic acid
10/30/2003US20030203918 Pharmaceutical composition comprising an anticholinergic and a heterocyclic compound
10/30/2003US20030203915 Compounds that are nitrosated and/or nitrosylated through one or more sites such as oxygen (hydroxyl condensation), sulfur (sulfhydryl condensation) and/or nitrogen
1 ... 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 ... 1151